Direct oral anticoagulant use in patients with antiphospholipid syndrome and unprovoked venous thromboembolism: a single centre experience

Affiliations

¹ Centre for Thrombosis and Haemostasis, St Thomas' Hospital, London, UK.
² Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Comment

Andrew J Doyle et al. Br J Haematol. 2021 Oct.

. 2021 Oct;195(2):276-278.

doi: 10.1111/bjh.17634. Epub 2021 Jul 6.

¹ Centre for Thrombosis and Haemostasis, St Thomas' Hospital, London, UK.
² Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

No abstract available

Comment on

Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome.
Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffatti A, Andreoli L, Tincani A, Cenci C, Prisco D, Fierro T, Gresele P, Cafolla A, De Micheli V, Ghirarduzzi A, Tosetto A, Falanga A, Martinelli I, Testa S, Barcellona D, Gerosa M, Banzato A. Pengo V, et al. Blood. 2018 Sep 27;132(13):1365-1371. doi: 10.1182/blood-2018-04-848333. Epub 2018 Jul 12. Blood. 2018. PMID: 30002145 Clinical Trial.
Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome: A Randomized Noninferiority Trial.
Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M, Vidal X, Riera-Mestre A, Castro-Salomó A, Cuquet-Pedragosa J, Ortiz-Santamaria V, Mauri-Plana M, Solé C, Cortés-Hernández J. Ordi-Ros J, et al. Ann Intern Med. 2019 Nov 19;171(10):685-694. doi: 10.7326/M19-0291. Epub 2019 Oct 15. Ann Intern Med. 2019. PMID: 31610549 Clinical Trial.

1. Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffatti A, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018;132(13):1365-71.
1. Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M, Vidal X, Riera-Mestre A, Castro-Salomó A, et al. Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial. Ann Intern Med. 2019;171(10):685-94.
1. Direct-acting oral anticoagulants (DOACs): increased risk of recurrent thrombotic events in patients with antiphospholipid syndrome - GOV.UK. Published 19th June 2019. https://www.gov.uk/drug-safety-update/direct-acting-oral-anticoagulants-.... Accessed 31st December 2020.
1. Arachchillage DRJ, Gomez K, Alikhan R, Anderson JAM, Lester W, Laffan M, et al. Addendum to British Society for Haematology Guidelines on Investigation and Management of Antiphospholipid syndrome, 2012 (Br. J. Haematol. 2012; 157: 47-58): use of direct acting oral anticoagulants. Br J Haematol. 2020;189(2):212-5.
1. Zuily S, Cohen H, Isenberg D, Woller SC, Crowther M, Dufrost V, et al. Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2020;18(9):2126-37.